FAST Innovation Seed Grant
The FAST Innovation Seed Grant funds early-stage, high-risk research to advance new therapies, targets, and biomarkers for Angelman syndrome.
Funder: Foundation for Angelman Syndrome Therapeutics (FAST)
Due Dates: Rolling (applications accepted year-round)
Funding Amounts: $10,000–$50,000 per award (seed funding for proof-of-concept research)
Summary: Supports innovative, early-stage, high-risk/high-reward research to advance the understanding and treatment of Angelman syndrome.
Description
The FAST Innovation Seed Grant is designed to accelerate the development of new therapies, therapeutic targets, and biomarkers for Angelman syndrome by supporting groundbreaking, early-stage, and high-risk/high-reward proof-of-concept research. This program provides seed funding to help researchers generate feasibility data that can position their ideas for larger grants and further development. The grant is open to both individual investigators and collaborative teams, including academic–industry partnerships, provided the research is clearly focused on Angelman syndrome and fits the program’s emphasis on novel, potentially transformative approaches.
